Modalities at this site: Mammalian | Cell Therapy | mRNA

AGC Biologics

YOKOHAMA FACILITY

New State-of-the-Art Facility in Japan

AGC Biologics is constructing a new site in Yokohama, Japan with plans to begin cell therapy operations in 2025. Mammalian and mRNA services are expected to begin in 2026, and the site plans to be fully operational by 2027. This site will expand our network capabilities in Japan, to meet growing global demand for biopharmaceutical CDMO services.

The new four-story facility will encompass 16,764m^2 of floor space and will include earthquake and tsunami protection. Solar panels will help with private power generation.

The facility will feature **dedicated spaces for process development (PD), quality control (QC), and manufacturing, including an automated warehouse**, to ensure efficient workflows.

Located adjacent to the AGC Yokohama Technical Center, which employs over 1,000 scientists working on new technology innovations, this site will leverage the processes and expertise of our other seven sites, which have over 25 years of experience, to provide end-to-end services.



Cell Therapy Services

- AGC Bio's expertise with internalizing autologous and allogeneic processes from the Center of Excellence in Milan
- Process transfer, development, cell manipulation, and engineering
- 2 x 25 L wave reactors
- 2 x CliniMACS Prodigy® platforms
- Capabilities for gene modification of cells by LVV/ RVV
- 6 x Grade B clean rooms
- Expertise in common used cell therapy types
  - T-cells
  - HSC / CD34
  - NK cells
  - MSC
  - Immune cells

Mammalian Services

- Process development services available at nearby Chiba site to begin projects
- Recombinant protein and monoclonal antibodies
- 4 x 2,000 L SUB
- 2 x 5,000 L SUB
- 2 x purification lines (1 of 2 lines to be implemented in the future)
- Titers up to 8 g/l for a single batch
- Offering one of the largest single-use bioreactors for a CDMO in Japan

mRNA Services

- In-network pDNA supply
- mRNA development and commercial production
- Production scales 0.5 – 12.5 L (disposable)
- 2 x IVT lines (0.5 - 25 L wave)
- 2 x purification lines - ÄKTA ready
- 2 x LNP lines - Nano Assemblr (1 of 2 lines to be implemented in the future)

Globally Aligned Quality System

- Documentation, policies, procedures
- Seven global sister sites sharing best practices to meet clinical and commercial needs

AGC Biologics
Your friendly CDMO expert

+1 425.485.1900
agcbio.com
contactus@agcbio.com

AGC
Life Science Company